As someone who used to do antibiotic R&D I strongly disagree with statement. Making a drug that kills bacteria but not the host is really damn hard.
Your point about the economic incentives is very true.
This statement seems to directly contradict what the article says:
"According to Sprenger, “there are no legal instruments to prohibit the use of a new antibiotic.” What that means is if a new antibiotic is released there’s no way to stop the world from overusing it. At current usage levels a new antibiotic, he says, would only have about two years on the market before bacterial resistance to it develops."
If the world overuses a new antibiotic then the pharma company should be swimming in cash. And if the pharma company isn't swimming in cash because people reserve them for rare cases, then it should not be possible for the world to overuse the new antibiotic.
Maybe cost is less of a factor in life threatening situations.
Compared to other drugs, antibiotics are relatively easy and cheap to discover or "invent" with modern techniques. Getting them through clinical trials, on the other hand, is not cheap.
Many clinicians should be less loose with antibiotics, sure. But, that won't eliminate resistance. Realistically, when superbugs become common, the incentives pharmaceutical companies face will shift. It's just there will be a lot of morbidity and mortality while we're waiting for their drugs to make it to hospital pharmacies.